Breakthroughs in Clinical Diabetes, Obesity and Metabolic Diseases

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Endocrinology".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 437

Special Issue Editors


E-Mail Website
Guest Editor
Department of Internal Medcine, Omoromachi Medical Center, Naha City 900-0011, Okinawa, Japan
Interests: diabetes; metabolic diseases; endocrinology; chronic kidney disease; diabetic nephropathy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
School of Medicine, Kanazawa Medical University, Kanazawa 920-0293, Japan
Interests: diabetes; lipoprotein metabolism; diabetic cardiovascular complications; diabetes treatment and education with ICT devices
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Comprehensive Internal Medicine, Shiga University of Medical Science, Shiga, Japan
2. Diabetes & Endocrinology Department, National Hospital Organization Higashiohmi General Medical Center, Higashiohmi, Japan
Interests: diabetes; metabolism; diabetic vascular complications; diabetes treatment in the elderly
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetes, obesity, and metabolic diseases continue to pose significant global health challenges, driving the need for groundbreaking therapeutic strategies.

Recent years have seen remarkable breakthroughs in the development of novel drugs, including weekly insulin, dual GLP-1 and GIP receptor agonists, and triple agonists targeting GLP-1, GIP, and glucagon receptors, as well as the emergence of oral GLP-1 receptor agonists. Additionally, advancements in medical technology are revolutionizing treatment approaches, offering new possibilities for managing these conditions more effectively.

Furthermore, precision medicine is playing an increasingly vital role in tailoring treatments based on individual patient characteristics, optimizing therapeutic outcomes.

In light of these exciting developments, we are pleased to introduce this Special Issue, entitled “Breakthroughs in Clinical Diabetes, Obesity and Metabolic Diseases”. We invite researchers and clinicians to contribute original studies, reviews, and case reports exploring the latest advancements in pharmacotherapy, precision medicine, and innovative technologies. We also highly encourage the submission of real-world data demonstrating clinical efficacy and practical applications.

We look forward to receiving your valuable contributions, which will help to shape the future of diabetes, obesity, and metabolic disease management.

Dr. Yuzuru Ohshiro
Prof. Dr. Kunimasa Yagi
Dr. Yasuhiro Maeno
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • obesity
  • metabolic diseases
  • new medicines
  • therapeutic innovations
  • precision medicine
  • advanced technology
  • weekly insulin
  • GLP-1 receptor agonists
  • real-world data

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 665 KiB  
Article
The Effects of 8-Week Hydrogen-Rich Water Consumption on Appetite, Body Composition, Sleep Quality, and Circulating Glucagon-like Peptide-1 in Obese Men and Women (HYDRAPPET): A Randomized Controlled Trial
by Nikola Todorovic, Sonja Baltic, David Nedeljkovic, Jovan Kuzmanovic, Darinka Korovljev, Dejan Javorac, Katarina Bijelic, Nebojsa Kladar, Alex Tarnava and Sergej M. Ostojic
Medicina 2025, 61(7), 1299; https://doi.org/10.3390/medicina61071299 - 18 Jul 2025
Viewed by 228
Abstract
Background and Objectives: Preliminary studies indicate that dihydrogen (H2) may affect molecular pathways involved in appetite regulation; however, its role in influencing patient-reported appetite outcomes in individuals with obesity remains uncertain. This randomized, placebo-controlled, double-blind trial aimed to evaluate the effects [...] Read more.
Background and Objectives: Preliminary studies indicate that dihydrogen (H2) may affect molecular pathways involved in appetite regulation; however, its role in influencing patient-reported appetite outcomes in individuals with obesity remains uncertain. This randomized, placebo-controlled, double-blind trial aimed to evaluate the effects of H2 supplementation on appetite, body composition, sleep quality, obesity-specific quality of life, and related biomarkers in obese men and women. Materials and Methods: The study included 36 participants (24 females; age 42.1 ± 13.2 years; BMI 30.8 ± 4.2 kg/m2) randomized to receive either 1.0 L of hydrogen-rich water (15 mg of H2) or 1.0 L of control water (0 mg of H2) daily for eight weeks. Results: The results demonstrated that hydrogen-rich water significantly mitigated cravings (p = 0.05), improved subjective sleep quality (p = 0.05), reduced total cholesterol (p = 0.02) and LDL cholesterol (p = 0.04), and increased plasma glucagon-like peptide-1 levels (p = 0.05) compared to the control. No severe adverse effects were reported throughout the trial. Conclusions: These findings suggest that hydrogen-rich water may serve as a safe and effective dietary strategy to address appetite regulation and related metabolic indices in individuals with obesity. The study is registered at ClinicalTrials.gov (NCT06722326). Full article
(This article belongs to the Special Issue Breakthroughs in Clinical Diabetes, Obesity and Metabolic Diseases)
Show Figures

Figure 1

Back to TopTop